Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $PALI alert in real time by email

Company on track to report topline data in first half of 2025

Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108

Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC

Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory and fibrotic diseases, today announced the completion of all five planned Single Ascending Dose (SAD) cohorts and the commencement of the Multiple Ascending Dose (MAD) cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC).

Preliminary data from the SAD portion of the study, which evaluated doses ranging from 15 mg to 450 mg of PALI-2108, support that the drug was well-tolerated across all dose levels. Importantly, there were no treatment-related dose reductions, serious adverse events (SAEs), or treatment-related laboratory abnormalities observed. Treatment-emergent adverse events (TEAEs) were mild and occurred only at the highest dose of 450 mg. Importantly, there were no EKG abnormalities or other serious safety concerns, underscoring the favorable safety profile of PALI-2108.

In addition to its safety and tolerability, preliminary pharmacokinetic (PK) analysis from the SAD portion of the study showed the delayed-release and extended-release characteristics of PALI-2108, which provides sustained, dose-dependent drug exposure with high local concentrations in the colon, a key feature for the targeted treatment of UC. This preliminary data provides strong support for the ongoing MAD portion of the trial, which aims to assess repeat dosing and further evaluate the safety and pharmacokinetics of PALI-2108 in both healthy volunteers and UC patients.

"We are excited to move from the SAD to the MAD portion of our Phase 1a/b study of PALI-2108, a significant milestone that brings us one-step closer to delivering an innovative, safe, and effective treatment option for UC patients," said Dr. Mitch Jones, Chief Medical Officer of Palisade. "The preliminary data from the SAD cohorts have reinforced our confidence in PALI-2108's safety profile, and we remain on track to report topline data in the first half of 2025."

The primary aim of this single-center Phase 1a/b study is to evaluate the safety, tolerability, and PK of PALI-2108 in healthy volunteers as well as to evaluate the safety, tolerability, PK and pharmacodynamics PD in patients with UC. Several PDE4 inhibitors have received market approval in both inflammatory and fibrotic disease; however, PALI-2108 represents a new chemical entity that has not been previously administered to humans. Biomarkers, including serum high sensitivity C-reactive protein (hsCRP), and fecal calprotectin (CalPro), along with colonic tissue histological assessments, will be employed to provide further insights into the drug's effects. The analysis of colon tissue will include the study drug and metabolite levels, PDE4 expression, cyclic adenosine monophosphate (cAMP) levels, Absolute Lymphocyte Count (ALC), and related PD biomarkers, which are crucial for understanding the drug's mechanism and efficacy.

For more information about the Phase 1a/b clinical study, visit clinicaltrials.gov and reference identifier NCT06663605.

About Palisade Bio 

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it can transform the treatment landscape. For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on preliminary data from the SAD portion of the Company's Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company's current expectations. Forward-looking statements involve risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company's current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company's product candidates, and its ability to serve those markets, including any potential revenue generated; the Company's ability to maintain the Nasdaq listing of its securities; the Company's ability to compete effectively in a competitive industry; the Company's ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company's ability to enter into commercial supply agreements; the Company's ability to attract and retain key scientific or management personnel; the accuracy of the Company's estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company's business, and operations, and supply. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775

PALI@jtcir.com



Primary Logo

Get the next $PALI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PALI

DatePrice TargetRatingAnalyst
2/2/2022$5.00Buy
Ladenburg Thalmann
8/31/2021$7.00Buy
Maxim Group
More analyst ratings

$PALI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

    Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs seen to date On track to report topline data in first half of 2025 Carlsbad, CA, March 14, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an upda

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

    PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis at Digestive Disease Week® (DDW) 2025 being held May 3–6, in San Diego, California. Participation details are as foll

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Participates in Virtual Investor "What This Means" Segment

    Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor "What This Means" segment. As part of this segment, Dr. Heyer discussed the Company's positive preclinical data for its lead product candidate, PALI-2108, w

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PALI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PALI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PALI
SEC Filings

See more

$PALI
Leadership Updates

Live Leadership Updates

See more
  • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

    Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Appoints Margery Fischbein to its Board of Directors

    Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

    Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Financials

Live finance-specific insights

See more
  • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

    Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more